Search results
Showing 3001 to 3050 of 4090 results for patient
This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Awaiting development Reference number: GID-TA11885 Expected publication date: TBC
Awaiting development Reference number: GID-TA11487 Expected publication date: 27 May 2027
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]
Awaiting development Reference number: GID-TA11526 Expected publication date: TBC
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]
Awaiting development Reference number: GID-TA11877 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
Awaiting development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Tildrakizumab for treating active psoriatic arthritis [ID6724]
Awaiting development Reference number: GID-TA11807 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]
Awaiting development Reference number: GID-TA11403 Expected publication date: 27 May 2027
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Awaiting development Reference number: GID-TA11303 Expected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Awaiting development Reference number: GID-TA11883 Expected publication date: 23 September 2027
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Awaiting development Reference number: GID-TA11878 Expected publication date: TBC
Awaiting development Reference number: GID-TA11861 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
Awaiting development Reference number: GID-TA11956 Expected publication date: TBC
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Awaiting development Reference number: GID-TA11659 Expected publication date: 13 May 2027
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Awaiting development Reference number: GID-TA11744 Expected publication date: TBC
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Awaiting development Reference number: GID-TA11758 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
In development Reference number: GID-TA11958 Expected publication date: 21 April 2027
Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]
Awaiting development Reference number: GID-TA11824 Expected publication date: TBC
Awaiting development Reference number: GID-TA11549 Expected publication date: TBC
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
In development Reference number: GID-TA11718 Expected publication date: TBC
Awaiting development Reference number: GID-TA11224 Expected publication date: TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Awaiting development Reference number: GID-TA11085 Expected publication date: TBC
Awaiting development Reference number: GID-TA11094 Expected publication date: TBC
Awaiting development Reference number: GID-TA11342 Expected publication date: TBC
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Awaiting development Reference number: GID-TA11721 Expected publication date: TBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]
In development Reference number: GID-TA11719 Expected publication date: TBC